Clinical trial results:
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, With Moderate to Severe Atopic Dermatitis

Summary

EudraCT number	2017-003651-29
Trial protocol	DE GB HU CZ PL
Global end of trial date	26 March 2019

Results information

Result version number	v1 (current)
This version publication date	04 October 2019
First version publication date	04 October 2019

Trial information

Trial identification

Sponsor protocol code	B7451012

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03349060
WHO universal trial number (UTN)	-
Other trial identifiers	Alias Study Number: MONO-1, Alias Study Number: JADE MONO-1

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-002312-PIP01-17
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 April 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 March 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of PF-04965842 compared with placebo in subjects aged 12 years and older with moderate to severe Atopic Dermatitis (AD).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 December 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 14
Country: Number of subjects enrolled	United States: 114
Country: Number of subjects enrolled	Australia: 51
Country: Number of subjects enrolled	Canada: 64
Country: Number of subjects enrolled	Czech Republic: 19
Country: Number of subjects enrolled	Germany: 64
Country: Number of subjects enrolled	Hungary: 12
Country: Number of subjects enrolled	Poland: 49
Worldwide total number of subjects	387
EEA total number of subjects	158

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	84
Adults (18-64 years)	287
From 65 to 84 years	16
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects with age greater than or equal to (>=) 12 years with moderate to severe AD and a body weight of >=40 kilogram were enrolled in the study. Eligible subjects had an option to enter into a long-term extension (LTE) study after completing 12 weeks of treatment in this study.

Pre-assignment

Screening details:

This study was conducted from 07-December-2017 to 26-March-2019 at 76 sites in 8 countries.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-04965842 100 mg

Arm description:

Participants were randomized to receive a tablet of PF-04965842 100 milligram (mg) and a tablet of matching placebo orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Arm type	Experimental
Investigational medicinal product name	PF-04965842
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-04965842 100 mg tablet administered orally once daily for 12 weeks.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

A tablet (matched to PF-04965842) of 100 mg administered orally once daily for 12 weeks.

Arm title	PF-04965842 200 mg

Arm description:

Participants were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Arm type	Experimental
Investigational medicinal product name	PF-04965842
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-04965842 200 mg, 2 tablets of 100 mg each administered orally once daily for 12 weeks.

Arm title	Placebo

Arm description:

Participants were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2 tablets (matched to PF-04965842) of 100 mg each administered orally once daily for 12 weeks.

Number of subjects in period 1	PF-04965842 100 mg	PF-04965842 200 mg	Placebo
Started	156	154	77
Completed	135	137	61
Not completed	21	17	16
Protocol deviation	2	2	1
Withdrawal By Parent/Guardian	-	1	-
Adverse event	9	9	7
Lack of efficacy	1	-	2
Unspecified	2	1	-
Consent withdrawn by subject	5	3	4
Medication error,no linked adverse event	-	-	1
Lost to follow-up	2	1	1

Baseline characteristics

Reporting groups	
Reporting group title	PF-04965842 100 mg
Reporting group description:	
Participants were randomized to receive a tablet of PF-04965842 100 milligram (mg) and a tablet of matching placebo orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	
Reporting group title	PF-04965842 200 mg
Reporting group description:	
Participants were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	
Reporting group title	Placebo
Reporting group description:	
Participants were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	

Reporting group values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo
Number of subjects	156	154	77
Age categorical			
The full analysis set (FAS) included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
Adolescents (12-17 years)	34	33	17
Adults (18-64 years)	118	110	59
From 65-84 years	4	11	1
85 years and over	0	0	0
Age Continuous			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: years			
arithmetic mean	32.6	33.0	31.5
standard deviation	± 15.4	± 17.4	± 14.4
Sex: Female, Male			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
Female	66	73	28
Male	90	81	49
Ethnicity (NIH/OMB)			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
Hispanic or Latino	10	4	6
Not Hispanic or Latino	144	149	71
Unknown or Not Reported	2	1	0
Race (NIH/OMB)			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
American Indian or Alaska Native	1	4	1
Asian	26	26	6

Native Hawaiian or Other Pacific Islander	0	1	0
Black or African American	15	11	6
White	113	104	62
More than one race	1	6	1
Unknown or Not Reported	0	2	1

Reporting group values	Total		
Number of subjects	387		
Age categorical			
The full analysis set (FAS) included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
Adolescents (12-17 years)	84		
Adults (18-64 years)	287		
From 65-84 years	16		
85 years and over	0		
Age Continuous			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
Female	167		
Male	220		
Ethnicity (NIH/OMB)			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
Hispanic or Latino	20		
Not Hispanic or Latino	364		
Unknown or Not Reported	3		
Race (NIH/OMB)			
The full analysis set included all randomized subjects who received at least 1 dose of study medication.			
Units: Subjects			
American Indian or Alaska Native	6		
Asian	58		
Native Hawaiian or Other Pacific Islander	1		
Black or African American	32		
White	279		
More than one race	8		
Unknown or Not Reported	3		

End points

End points reporting groups

Reporting group title	PF-04965842 100 mg
Reporting group description:	
Participants were randomized to receive a tablet of PF-04965842 100 milligram (mg) and a tablet of matching placebo orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	
Reporting group title	PF-04965842 200 mg
Reporting group description:	
Participants were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	
Reporting group title	Placebo
Reporting group description:	
Participants were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Participants who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	

Primary: Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12

End point title	Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12
End point description:	
IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0=clear, no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation and no oozing/crusting; 2=mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3=moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4=severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp. FAS=all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed"(N)=subjects evaluable for this end point.	
End point type	Primary
End point timeframe:	
Baseline, Week 12	

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	153	76	
Units: percentage of subjects				
number (not applicable)	23.7	43.8	7.9	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

The estimate and confidence interval (CI) for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0037 [1]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	15.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.8
upper limit	24.8

Notes:

[1] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	36
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.2
upper limit	45.7

Notes:

[2] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Primary: Percentage of Subjects Achieving Eczema Area and Severity Index (EASI) Response of >=75 Percent (%) Improvement From Baseline at Week 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index (EASI) Response of >=75 Percent (%) Improvement From Baseline at Week 12

End point description:

EASI evaluates severity of subject's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD [erythema (E), induration/papulation (I), excoriation (Ex) and lichenification (L)] scored separately for each of 4 body regions (head and neck (h), upper limbs (u), trunk [including axillae and groin)] (t) and lower limbs [including buttocks] (l)) on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score

was based upon % BSA with AD in body region: 0(0%), 1(>0-<10%), 2(10-<30%), 3(30-<50%), 4(50-<70%), 5(70-<90%) and 6(90-100%). Total EASI score= 0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au*(Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al*(El+Il+ExI+Ll); (A =EASI area score) ranged from 0.0-72.0, higher scores=greater severity. FAS=all randomized subjects who received at least 1 dose of study medication. Here, N=subjects evaluable for this end

End point type	Primary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	153	76	
Units: percentage of subjects				
number (not applicable)	39.7	62.7	11.8	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	27.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.4
upper limit	38.3

Notes:

[3] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel

Parameter estimate	Difference in Percentage
Point estimate	51
Confidence interval	
level	95 %
sides	2-sided
lower limit	40.5
upper limit	61.5

Secondary: Percentage of Subjects With at Least 4 Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Week 2, 4, 8 and 12: Full Analysis Set (FAS)

End point title	Percentage of Subjects With at Least 4 Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Week 2, 4, 8 and 12: Full Analysis Set (FAS)

End point description:

Subjects were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	147	147	74	
Units: percentage of subjects				
number (not applicable)				
Week 2	20.4	45.6	2.7	
Week 4	32.2	58.8	17.2	
Week 8	34.3	59.9	14.4	
Week 12	37.7	57.2	15.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: Each complete imputed data set was analyzed using the Cochran-Mantel-Haenszel (CMH) risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004

Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	18
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.2
upper limit	25.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	42.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.6
upper limit	51.4

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0251
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	15
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.9
upper limit	28

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Week 4: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	41.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	27.8
upper limit	54.4

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Week 8: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0019
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.4
upper limit	32.7

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Week 8: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.	
Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	45.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.7
upper limit	57.8

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	22.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.3
upper limit	34.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	221
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	41.7
Confidence interval	
level	95 %
sides	2-sided

lower limit	29.6
upper limit	53.9

Secondary: Percentage of Subjects With at Least 4 Points Improvement From Baseline in the Numerical Rating Scale for Severity of Pruritus at Week 2, 4 and 12: Per Protocol Analysis Set (PPAS)

End point title	Percentage of Subjects With at Least 4 Points Improvement From Baseline in the Numerical Rating Scale for Severity of Pruritus at Week 2, 4 and 12: Per Protocol Analysis Set (PPAS)

End point description:

Subjects were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity. Per-protocol analysis set included all randomized subjects who received at least 1 dose of study medication and who had no major protocol violations. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	127	126	54	
Units: percentage of subjects				
number (not applicable)				
Week 2	20.5	47.6	3.7	
Week 4	34.0	63.3	20.7	
Week 12	41.1	60.6	12.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0055
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	16.3
Confidence interval	
level	95 %
sides	2-sided

lower limit	7.4
upper limit	25.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	43.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.1
upper limit	53.6

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1138
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	12.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	28

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were

combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	41.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.2
upper limit	57.4

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.3
upper limit	42.1

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: Each complete imputed data set was analyzed using the CMH risk difference method adjusting by randomization strata, separately for each week. Results from multiply imputed data sets were combined using Rubin's rules to obtain treatment difference, 95% CI and p-value.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	47.8
Confidence interval	

level	95 %
sides	2-sided
lower limit	34.6
upper limit	61.1

Secondary: Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 2, 4, 8 and 12: Full Analysis Set

End point title	Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 2, 4, 8 and 12: Full Analysis Set

End point description:

PSAAD is a daily subject reported symptom electronic diary. Subjects rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin [lighter or darker], bleeding from skin, seeping or oozing fluid from skin [other than blood], and skin swelling). Subject had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	137	138	68	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-1.5 (-1.7 to -1.2)	-2.1 (-2.3 to -1.8)	-0.5 (-0.8 to -0.1)	
Change at Week 4	-1.8 (-2.1 to -1.5)	-3.0 (-3.2 to -2.7)	-0.7 (-1.1 to -0.3)	
Change at Week 8	-2.2 (-2.5 to -1.8)	-3.1 (-3.5 to -2.8)	-1.2 (-1.7 to -0.7)	
Change at Week 12	-2.2 (-2.6 to -1.9)	-3.2 (-3.6 to -2.8)	-1.1 (-1.7 to -0.6)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: Mixed model repeated measure (MMRM) contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	205

Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in least squares (LS) mean
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	206
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	-1.2

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6

upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	206
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	-1.7

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0035
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	-0.3

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	206
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	-1.3

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	-0.4

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	206
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.1
Confidence interval	
level	95 %

sides	2-sided
lower limit	-2.7
upper limit	-1.4

Secondary: Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis Total Score at Week 12: Per Protocol Analysis Set

End point title	Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis Total Score at Week 12: Per Protocol Analysis Set

End point description:

PSAAD is a daily subject reported symptom electronic diary. subjects rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin [lighter or darker], bleeding from skin, seeping or oozing fluid from skin [other than blood], and skin swelling). Subject had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition. Per-protocol analysis set included all randomized subjects who received at least 1 dose of study medication and who had no major protocol violations. Here, N=subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	115	117	50	
Units: units on a scale				
least squares mean (confidence interval 95%)	-2.4 (-2.8 to -2.1)	-3.4 (-3.8 to -3.0)	-1.1 (-1.7 to -0.5)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	165
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.3
Confidence interval	

level	95 %
sides	2-sided
lower limit	-2
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	-1.6

Secondary: Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale for Severity of Pruritus

End point title	Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale for Severity of Pruritus

End point description:

Subjects were asked to assess their worst itching/pruritus due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst itch imaginable), where higher scores indicated greater severity. 95% CI was based on the Brookmeyer and Crowley method. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point. 99999 signifies that upper limit was not evaluable since very less events were observed.

End point type	Secondary

End point timeframe:

Baseline up to Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	73	106	23	
Units: days				
median (confidence interval 95%)	84.0 (56.0 to 99999)	14.0 (11.0 to 29.0)	92.0 (85.0 to 99999)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0071 [4]
Method	Logrank

Notes:

[4] - P-value was controlled by randomization strata.

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [5]
Method	Logrank

Notes:

[5] - P-value was controlled by randomization strata.

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=75% Improvement From Baseline at Week 2, 4 and 8

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=75% Improvement From Baseline at Week 2, 4 and 8

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD [erythema (E), induration/papulation (I), excoriation (Ex) and lichenification (L) scored separately for each of 4 body regions (head and neck (h), upper limbs (u), trunk [including axillae and groin)] (t) and lower limbs [including buttocks] (l)) on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0(0%), 1(>0-<10%), 2(10-<30%), 3(30-<50%), 4(50-<70%), 5(70-<90%) and 6(90-100%). Total EASI score ranged from 0.0-72.0, higher scores = greater severity of AD. FAS=all randomized subjects who received at least 1 dose of study medication. Here, N=subjects evaluable for this end point and "Number Analyzed" (n) signifies the number of subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	155	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154,77)	10.3	24.0	3.9	
Week 4 (n=152, 152, 76)	27.6	47.4	14.5	
Week 8 (n=154, 154, 75)	38.3	57.8	13.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0869 [6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	13.3

Notes:

[6] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	12
upper limit	28.6

Notes:

[7] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0259 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	13.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.6
upper limit	23.6

Notes:

[8] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.7
upper limit	44.2

Notes:

[9] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.0001 [10]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	25
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.2
upper limit	35.8

Notes:

[10] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [11]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	44.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.6
upper limit	55.6

Notes:

[11] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Investigator's Global Assessment Response of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 2, 4 and 8

End point title	Percentage of Subjects Achieving Investigator's Global Assessment Response of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 2, 4 and 8

End point description:

IGA assesses severity of AD on a 5 point scale (0-4, higher scores indicate more severity), 0=clear, no inflammatory signs of AD; 1=almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2=mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3=moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4=severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp. FAS=all randomized subjects who received at least 1 dose of study medication. Here, N=subjects evaluable for this end point and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	155	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154, 77)	3.9	9.7	0	
Week 4 (152, 152, 76)	10.5	27.0	5.3	
Week 8 (153, 154, 75)	20.3	35.7	6.7	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0802 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	8.5

Notes:

[12] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0045 [13]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.8
Confidence interval	
level	95 %

sides	2-sided
lower limit	4
upper limit	15.7

Notes:

[13] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1888 [14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	12.4

Notes:

[14] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	21.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	13
upper limit	30.5

Notes:

[15] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo

Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0071 [16]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	13.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.2
upper limit	22.4

Notes:

[16] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [17]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	29.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.8
upper limit	38.7

Notes:

[17] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Investigator's Global Assessment Response of Clear (0) at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Investigator's Global Assessment Response of Clear (0) at Week 2, 4, 8 and 12

End point description:

IGA assesses severity of AD on a 5 point scale (0-4, higher scores indicate more severity), 0=clear, no inflammatory signs of AD; 1=almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2=mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3=moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4=severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp. FAS=all randomized subjects who received at least 1 dose of study medication. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154, 77)	0	0	0	
Week 4 (n=152, 152, 76)	0	6.6	0	
Week 8 (n=153, 154, 75)	4.6	11.7	0	
Week 12 (n=156, 153, 76)	7.1	13.1	0	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.8

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	3.9

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0234 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	11.7

Notes:

[18] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0592 [19]
Method	Cochran-Mantel-Haenszel

Parameter estimate	Difference in Percentage
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	9.5

Notes:

[19] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0022 [20]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.5
upper limit	17.9

Notes:

[20] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.019 [21]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.7
upper limit	12.3

Notes:

[21] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001 [22]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	13.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.7
upper limit	19.4

Notes:

[22] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=50% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=50% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD [erythema (E), induration/papulation (I), excoriation (Ex) and lichenification (L) scored separately for each of 4 body regions (head and neck (h), upper limbs (u), trunk [including axillae and groin)] (t) and lower limbs [including buttocks] (l)) on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0(0%), 1(>0-<10%), 2(10-<30%), 3(30-<50%), 4(50-<70%), 5(70-<90%) and 6(90-100%). Total EASI score ranged from 0.0-72.0, higher scores = greater severity of AD. FAS=randomized subjects who received at least 1 dose of study medication. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154, 77)	34.2	55.2	10.4	
Week 4 (n=152, 152, 76)	54.6	73.7	21.1	
Week 8 (n=154, 154, 75)	57.8	76.6	24.0	
Week 12 (n=156, 153, 76)	57.7	75.8	22.4	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [23]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	24
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.9
upper limit	34.1

Notes:

[23] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [24]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	45.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	34.7
upper limit	55.5

Notes:

[24] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference

for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [25]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.6
upper limit	45.4

Notes:

[25] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [26]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	52.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	41.2
upper limit	64.2

Notes:

[26] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [27]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	34.1
Confidence interval	
level	95 %

sides	2-sided
lower limit	21.9
upper limit	46.3

Notes:

[27] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	52.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	41.3
upper limit	64.6

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [28]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	35.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.3
upper limit	47.4

Notes:

[28] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [29]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	53.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	42
upper limit	65

Notes:

[29] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=90% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=90% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD [erythema (E), induration/papulation (I), excoriation (Ex) and lichenification (L) scored separately for each of 4 body regions (head and neck (h), upper limbs (u), trunk [including axillae and groin)] (t) and lower limbs [including buttocks] (l)) on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0(0%), 1(>0-<10%), 2(10-<30%), 3(30-<50%), 4(50-<70%), 5(70-<90%) and 6(90-100%). Total EASI score ranged from 0.0-72.0, higher scores = greater severity of AD. FAS=all randomized subjects who received at least 1 dose of study medication. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154, 77)	1.9	5.2	1.3	
Week 4 (n=152, 152, 76)	7.9	24.3	3.9	
Week 8 (n=154, 154, 75)	14.3	33.1	5.3	
Week 12 (n=156, 153, 76)	18.6	38.6	5.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7285 [30]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	5.2

Notes:

[30] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1448 [31]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	9.2

Notes:

[31] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2576 [32]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	3.9
Confidence interval	

level	95 %
sides	2-sided
lower limit	-2.6
upper limit	10.5

Notes:

[32] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001 [33]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	12
upper limit	28.9

Notes:

[33] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0423
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	16.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [34]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.7
upper limit	37.2

Notes:

[34] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0066 [35]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	13.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.4
upper limit	21.2

Notes:

[35] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [36]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.4
Confidence interval	
level	95 %
sides	2-sided

lower limit	24.3
upper limit	42.5

Notes:

[36] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of 100% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of 100% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD [erythema (E), induration/papulation (I), excoriation (Ex) and lichenification (L) scored separately for each of 4 body regions (head and neck (h), upper limbs (u), trunk [including axillae and groin)] (t) and lower limbs [including buttocks] (l)) on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0(0%), 1(>0-<10%), 2(10-<30%), 3(30-<50%), 4(50-<70%), 5(70-<90%) and 6(90-100%). Total EASI score ranged from 0.0-72.0, higher scores = greater severity of AD. FAS=all randomized subjects who received at least 1 dose of study medication. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154, 77)	0	0	0	
Week 4 (n=152, 152, 76)	0	6.6	0	
Week 8 (n=154, 154, 75)	4.5	11.7	0	
Week 12 (n=156, 153, 76)	6.4	13.1	0	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %

sides	2-sided
lower limit	-3.8
upper limit	3.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.8

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	3.9

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0234 [37]

Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	11.7

Notes:

[37] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0604 [38]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	9.5

Notes:

[38] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0022 [39]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.5
upper limit	17.9

Notes:

[39] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0255 [40]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.2
upper limit	11.6

Notes:

[40] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001 [41]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	13.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.7
upper limit	19.4

Notes:

[41] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Eczema Area and Severity Index Total Score at Week 2, 4, 8 and 12

End point title	Change From Baseline in Eczema Area and Severity Index Total Score at Week 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD [erythema (E), induration/papulation (I), excoriation (Ex) and lichenification (L) scored separately for each of 4 body regions (head and neck (h), upper limbs (u), trunk [including axillae and groin)] (t) and lower limbs [including buttocks] (l)) on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0(0%), 1(>0-<10%), 2(10-<30%), 3(30-<50%), 4(50-<70%), 5(70-<90%) and 6(90-100%). Total EASI score ranged from 0.0-72.0, higher scores = greater severity of AD. FAS=all randomized subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-9.8 (-11.3 to -8.4)	-14.7 (-16.1 to -13.3)	-4.1 (-6.1 to -2.1)	
Change at Week 4	-14.7 (-16.3 to -13.1)	-19.6 (-21.2 to -17.9)	-6.8 (-9.2 to -4.5)	
Change at Week 8	-16.3 (-18.1 to -14.6)	-21.3 (-23.0 to -19.5)	-7.8 (-10.3 to -5.3)	
Change at Week 12	-16.6 (-18.4 to -14.7)	-22.3 (-24.1 to -20.4)	-8.2 (-10.9 to -5.5)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.2
upper limit	-3.3

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-10.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13
upper limit	-8.1

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-7.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.7
upper limit	-5

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-12.7
Confidence interval	
level	95 %
sides	2-sided

lower limit	-15.6
upper limit	-9.9

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-8.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.6
upper limit	-5.5

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-13.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.5
upper limit	-10.4

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an

unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-8.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.6
upper limit	-5.1

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.3
upper limit	-10.8

Secondary: Change From Baseline in Percentage Body Surface Area at Week 2, 4, 8 and 12

End point title	Change From Baseline in Percentage Body Surface Area at Week 2, 4, 8 and 12

End point description:

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of subject's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint=10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. % BSA for a body region was calculated as=total number of handprints in a body region*% surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0-100%, with higher values representing greater severity of AD. FAS=all randomized subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: Percentage BSA				
least squares mean (confidence interval 95%)				
Change at Week 2	-11.8 (-14.3 to -9.4)	-18.8 (-21.3 to -16.4)	-4.0 (-7.6 to -0.5)	
Change at Week 4	-20.2 (-23.0 to -17.4)	-27.0 (-29.8 to -24.2)	-8.5 (-12.5 to -4.5)	
Change at Week 8	-23.2 (-26.3 to -20.2)	-31.5 (-34.6 to -28.5)	-8.9 (-13.3 to -4.5)	
Change at Week 12	-25.1 (-28.3 to -22.0)	-33.4 (-36.6 to -30.3)	-11.4 (-16.0 to -6.8)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-7.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.1
upper limit	-3.5

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231

Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-14.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19
upper limit	-10.5

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.6
upper limit	-6.9

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-18.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.4

upper limit	-13.6

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-14.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.7
upper limit	-9

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-22.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28
upper limit	-17.3

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-13.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.3
upper limit	-8.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.6
upper limit	-16.5

Secondary: Percentage of Subjects With Percentage Body Surface Area Less Than (<) 5% at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Percentage Body Surface Area Less Than (<) 5% at Week 2, 4, 8 and 12

End point description:

4 body regions were evaluated: head and neck (h), upper limbs (u), trunk (including axillae and groin) (t) and lower limbs (including buttocks) (l). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of subject's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for h, 20 for u, 30 for t and 40 for l. Surface area of body region equivalent to 1 handprint: 1 handprint:10%=h, 5%=u, 3.33%=t and 2.5%=l. % BSA for a body region was calculated as=total number of handprints in a body region*% surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0-100%, with higher values representing greater severity of AD. FAS=all randomized subjects who received at least 1 dose of study medication. Here, n=subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	77	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=155, 154, 77)	2.6	5.2	1.3	
Week 4 (n=152, 152, 76)	8.6	27.6	3.9	
Week 8 (n=154, 154, 75)	16.2	33.1	6.7	
Week 12 (n=156, 153, 76)	21.2	38.6	5.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.521 [42]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	6

Notes:

[42] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1416 [43]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	9.3

Notes:

[43] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2002 [44]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	11.2

Notes:

[44] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [45]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	23.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.1
upper limit	32.2

Notes:

[45] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0434 [46]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	17.9

Notes:

[46] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [47]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	26.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.1
upper limit	36.2

Notes:

[47] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0019 [48]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	15.8
Confidence interval	

level	95 %
sides	2-sided
lower limit	7.5
upper limit	24

Notes:

[48] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [49]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	24
upper limit	42.7

Notes:

[49] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With Scoring Atopic Dermatitis (SCORAD) Response of >=50% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Scoring Atopic Dermatitis (SCORAD) Response of >=50% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

SCORAD:scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region-head and neck 9%, upper limbs 9% each, lower limbs 18% each, anterior trunk 18%, back 18%, 1% for genitals; score for each region was added to give A(0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2, severe=3; scores were summed to give B(0-18). C: pruritus and sleep, each of these 2 were scored by subject/caregiver using visual analogue scale (VAS) where "0"=no itch/no sleeplessness; "10"=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give C (0-20). The SCORAD was calculated: A/5 + 7*B/2 + C;range=0-103;higher values=worse outcome. FAS analysis set."N"=subjects evaluable for this end point; "n"=subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	148	150	75	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=148, 150, 75)	14.9	34.0	4.0	
Week 4 (n=145, 148, 70)	34.5	50.7	12.9	
Week 8 (n=146, 148, 72)	36.3	54.1	12.5	
Week 12 (n=145, 146, 73)	36.6	56.8	16.4	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0151 [50]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	10.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.3
upper limit	18.3

Notes:

[50] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [51]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	30
Confidence interval	
level	95 %
sides	2-sided
lower limit	21
upper limit	39

Notes:

[51] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001 [52]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	21.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.2
upper limit	32.3

Notes:

[52] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [53]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	37.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.6
upper limit	49.3

Notes:

[53] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.0003 [54]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	23.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.6
upper limit	34.3

Notes:

[54] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [55]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	41.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	30.7
upper limit	52.7

Notes:

[55] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0026 [56]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	19.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.1
upper limit	31.1

Notes:

[56] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [57]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	40
Confidence interval	
level	95 %
sides	2-sided
lower limit	28.3
upper limit	51.7

Notes:

[57] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With Scoring Atopic Dermatitis Response of >=75% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Scoring Atopic Dermatitis Response of >=75% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

SCORAD:scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region-head and neck 9%, upper limbs 9% each, lower limbs 18% each, anterior trunk 18%, back 18%, 1% for genitals; score for each region was added to give A(0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2, severe=3; scores were summed to give B(0-18). C: pruritus and sleep, each of these 2 were scored by subject/caregiver using visual analogue scale (VAS) where "0"=no itch/no sleeplessness; "10"=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give C (0-20). The SCORAD was calculated: A/5 + 7*B/2 + C;range=0-103;higher values=worse outcome. FAS analysis set."N"=subjects evaluable for this end point; "n"=subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	148	150	75	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=148, 150, 75)	1.4	6.0	0	
Week 4 (n=145, 148, 70)	2.8	18.2	2.9	

Week 8 (n=146, 148, 72)	12.3	23.6	1.4	
Week 12 (n=145, 146, 73)	12.4	30.8	4.1	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3151 [58]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	5.6

Notes:

[58] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0292 [59]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	11.3

Notes:

[59] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference

for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9402 [60]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	5.5

Notes:

[60] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0019 [61]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	15.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.3
upper limit	23.2

Notes:

[61] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0078 [62]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	10.8
Confidence interval	
level	95 %

sides	2-sided
lower limit	4.2
upper limit	17.4

Notes:

[62] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [63]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	22.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.2
upper limit	30.1

Notes:

[63] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0528 [64]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	8.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	15.3

Notes:

[64] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [65]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	26.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.6
upper limit	35.3

Notes:

[65] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Scoring Atopic Dermatitis: Visual Analogue Scale of Sleep Loss at Week 2, 4, 8 and 12

End point title	Change From Baseline in Scoring Atopic Dermatitis: Visual Analogue Scale of Sleep Loss at Week 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9% upper limbs 9% each, lower limbs 18% each, anterior trunk 18%, back 18%, 1% for genitals; score for each region was added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2, severe=3. The severity scores added to give B (0-18). C: pruritus and sleep loss, each of these 2 were scored by subject/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness added to give C (0-20). The SCORAD was calculated: A/5 + 7*B/2 + C; range=0-103; higher values=worse outcome. FAS analysis set."N"=subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	153	77	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-2.1 (-2.4 to -1.7)	-3.1 (-3.5 to -2.8)	-0.8 (-1.3 to -0.3)	
Change at Week 4	-2.5 (-2.9 to -2.1)	-3.7 (-4.1 to -3.3)	-1.0 (-1.5 to -0.4)	
Change at Week 8	-2.8 (-3.2 to -2.4)	-3.8 (-4.2 to -3.4)	-1.3 (-1.9 to -0.7)	
Change at Week 12	-2.9 (-3.4 to -2.5)	-3.7 (-4.2 to -3.3)	-1.6 (-2.2 to -1.0)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	-1.7

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified

Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	-0.9

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	-2

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	-0.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	-1.8

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	-1.4

Secondary: Change From Baseline in Scoring Atopic Dermatitis: Total Score at Week 2, 4, 8 and 12

End point title	Change From Baseline in Scoring Atopic Dermatitis: Total Score at Week 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9% upper limbs 9% each, lower limbs 18% each, anterior trunk 18%, back 18%, 1% for genitals; score for each region was added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2, severe=3. The severity scores added to give B (0-18). C: pruritus and sleep loss, each of these 2 were scored by subject/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness added to give C (0-20). The SCORAD was calculated: A/5 + 7*B/2 + C; range=0-103; higher values=worse outcome. FAS analysis set."N"=subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	150	151	75	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-16.4 (-18.7 to -14.2)	-24.4 (-26.7 to -22.2)	-5.5 (-8.7 to -2.4)	
Change at Week 4	-23.1 (-25.8 to -20.4)	-32.6 (-35.3 to -29.9)	-10.5 (-14.4 to -6.7)	
Change at Week 8	-26.0 (-29.1 to -23.0)	-33.7 (-36.7 to -30.7)	-11.7 (-16.0 to -7.4)	
Change at Week 12	-27.0 (-30.2 to -23.7)	-35.5 (-38.7 to -32.3)	-13.6 (-18.3 to -9.0)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-10.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.8
upper limit	-7

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-18.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.7
upper limit	-15.1

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified

Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-12.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.3
upper limit	-7.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-22.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.8
upper limit	-17.3

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-14.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.5
upper limit	-9

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.2
upper limit	-16.7

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	225
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-13.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19
upper limit	-7.7

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-21.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.5
upper limit	-16.3

Secondary: Percentage of Subjects Achieving >=1 Point Improvement From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving >=1 Point Improvement From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis at Week 2, 4, 8 and 12

End point description:

PSAAD is a daily subject reported symptom electronic diary. Subjects rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin [lighter or darker], bleeding from skin, seeping or oozing fluid from skin [other than blood], and skin swelling). Subject had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0(no symptoms) to 10(extreme symptoms). Total PSAAD score=arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point and "Number Analyzed" signifies number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	135	136	67	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=133, 135, 67)	51.1	68.9	28.4	
Week 4 (n=134, 132, 67)	62.7	77.3	44.8	
Week 8 (n=133, 136, 67)	60.9	69.1	44.8	
Week 12 (n=132, 128, 66)	61.4	70.3	40.9	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0028 [66]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	22.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.7
upper limit	35.9

Notes:

[66] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	203
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [67]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	40.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	27.1
upper limit	53.2

Notes:

[67] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0217 [68]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage

Point estimate	17.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	31.4

Notes:

[68] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	203
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [69]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	32.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.5
upper limit	45.9

Notes:

[69] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0363 [70]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	15.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.4
upper limit	30

Notes:

[70] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	203
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011 [71]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	23.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.8
upper limit	37.7

Notes:

[71] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.008 [72]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.8
upper limit	34.5

Notes:

[72] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	203
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [73]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	29.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	15
upper limit	43.3

Notes:

[73] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 2, 4, 8 and 12

End point title	Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 2, 4, 8 and 12

End point description:

DLQI is a 10-item questionnaire that measures the impact of skin disease on subject's (aged above 17 years) quality of life over the last week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of subjects. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	121	119	60	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-5.9 (-6.9 to -5.0)	-7.6 (-8.6 to -6.7)	-2.1 (-3.5 to -0.8)	
Change at Week 4	-6.8 (-7.8 to -5.9)	-9.6 (-10.6 to -8.7)	-3.5 (-4.9 to -2.1)	
Change at Week 8	-6.8 (-7.9 to -5.6)	-9.3 (-10.5 to -8.2)	-4.0 (-5.6 to -2.3)	
Change at Week 12	-7.0 (-8.1 to -5.8)	-9.1 (-10.3 to -8.0)	-4.2 (-5.9 to -2.5)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority

P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.4
upper limit	-2.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	-3.9

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5
upper limit	-1.7

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-6.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.8
upper limit	-4.5

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0075
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	-0.7

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.4
upper limit	-3.3

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0072
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	-0.8

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-4.9
Confidence interval	
level	95 %
sides	2-sided

lower limit	-6.9
upper limit	-2.9

Secondary: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 2, 4, 8 and 12

End point title	Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 2, 4, 8 and 12

End point description:

CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	32	16	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-4.5 (-5.8 to -3.2)	-5.8 (-7.1 to -4.5)	-3.3 (-5.1 to -1.4)	
Change at Week 4	-5.3 (-6.7 to -4.0)	-8.2 (-9.5 to -6.8)	-1.8 (-3.8 to 0.2)	
Change at Week 8	-5.2 (-6.9 to -3.6)	-7.5 (-9.2 to -5.9)	-3.1 (-5.6 to -0.6)	
Change at Week 12	-6.4 (-7.9 to -5.0)	-7.5 (-8.9 to -6.0)	-3.9 (-6.1 to -1.7)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.275
Method	Mixed models analysis
Parameter estimate	Difference in LS mean

Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	1

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.028
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	-0.3

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0051
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	-1.1

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	-4

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1706
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	0.9

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0048

Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-4.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.4
upper limit	-1.4

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0629
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	0.1

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.01
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	-0.9

Secondary: Percentage of Subjects With Baseline Dermatology Life Quality Index Score >=2 and Achieving <2 DLQI Score at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Baseline Dermatology Life Quality Index Score >=2 and Achieving <2 DLQI Score at Week 2, 4, 8 and 12

End point description:

DLQI is a 10-item questionnaire that measures the impact of skin disease on subject's (aged above 17 years) quality of life over the last week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of subjects. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point and "Number Analyzed" signifies number of subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	120	119	59	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=120, 119, 59)	10.0	23.5	3.4	
Week 4 (n=118, 117, 59)	15.3	32.5	8.5	
Week 8 (n=118, 119, 57)	17.8	35.3	8.8	
Week 12 (n=119, 119, 58)	20.2	31.9	12.1	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1238 [74]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.6
Confidence interval	
level	95 %
sides	2-sided

lower limit	-0.7
upper limit	13.9

Notes:

[74] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	178
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008 [75]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	11
upper limit	29.2

Notes:

[75] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2091 [76]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	16.4

Notes:

[76] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	178

Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005 [77]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	24
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.9
upper limit	35

Notes:

[77] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1161 [78]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	19.1

Notes:

[78] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	178
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 [79]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	26.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.3
upper limit	37.7

Notes:

[79] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1837 [80]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	8.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	19.1

Notes:

[80] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	178
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0046 [81]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	19.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.1
upper limit	31.6

Notes:

[81] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With Baseline Children’s Dermatology Life Quality Index Score >=2 and Achieving <2 CDLQI Score at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Baseline Children’s Dermatology Life Quality Index Score >=2 and Achieving <2 CDLQI Score at Week 2, 4, 8 and 12

End point description:

CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total

score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, “Number of Subjects Analyzed” signifies subjects evaluable for this end point and "Number Analyzed” signifies number of subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	31	31	16	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=31, 31, 16)	3.2	0	0	
Week 4 (n=30, 31, 15)	13.3	9.7	0	
Week 8 (n=31, 31, 14)	12.9	12.9	7.1	
Week 12 (n=31, 31, 15)	19.4	9.7	0	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4795 [82]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.3
upper limit	16.6

Notes:

[82] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47

Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.7
upper limit	12.7

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1452 [83]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	13.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	30.3

Notes:

[83] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2232 [84]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	25.4

Notes:

[84] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5707 [85]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.7
upper limit	25.4

Notes:

[85] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5777 [86]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.6
upper limit	25.1

Notes:

[86] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.0744 [87]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	19.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	37.5

Notes:

[87] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2232 [88]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	25.4

Notes:

[88] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With Baseline Dermatology Life Quality Index Score >=4 and Achieving >=4 Point Improvement From Baseline in DLQI Score at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Baseline Dermatology Life Quality Index Score >=4 and Achieving >=4 Point Improvement From Baseline in DLQI Score at Week 2, 4, 8 and 12

End point description:

DLQI is a 10-item questionnaire that measures the impact of skin disease on subject's (aged above 17 years) quality of life over the last week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of subjects. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, “Number of Subjects Analyzed” signifies subject who were evaluable for this end point and "Number Analyzed” signifies number of subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	117	117	56	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=117, 117, 56)	67.5	71.8	35.7	
Week 4 (n=115, 115, 56)	72.2	85.2	51.8	
Week 8 (n=116, 117, 54)	64.7	82.1	48.1	
Week 12 (n=116, 117, 55)	67.2	72.6	43.6	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [89]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	31.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.2
upper limit	46

Notes:

[89] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [90]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	35.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.5
upper limit	49.9

Notes:

[90] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.009 [91]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.2
upper limit	35.6

Notes:

[91] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [92]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	19
upper limit	47.7

Notes:

[92] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.0421 [93]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	16.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	32.4

Notes:

[93] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [94]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.9
upper limit	48.8

Notes:

[94] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0035 [95]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	23.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.2
upper limit	38.8

Notes:

[95] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 [96]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.8
upper limit	43.9

Notes:

[96] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With Baseline Children's Dermatology Life Quality Index Score >=2.5 and Achieving >=2.5 Point Improvement From Baseline in CDLQI Score at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With Baseline Children's Dermatology Life Quality Index Score >=2.5 and Achieving >=2.5 Point Improvement From Baseline in CDLQI Score at Week 2, 4, 8 and 12

End point description:

CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, “Number of Subjects Analyzed” signifies subjects evaluable for this end point and "Number Analyzed” signifies number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	30	31	16	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=30, 31, 16)	73.3	74.2	56.3	
Week 4 (n=29, 31, 15)	69.0	83.9	40.0	

Week 8 (n=30, 31, 14)	66.7	77.4	35.7	
Week 12 (n=30, 31, 15)	73.3	83.9	53.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2497 [97]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	17.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.1
upper limit	43.2

Notes:

[97] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2371
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	17.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9
upper limit	43.3

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference

for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0697 [98]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	58.3

Notes:

[98] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003 [99]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	43.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.2
upper limit	71.7

Notes:

[99] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0583 [100]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	31
Confidence interval	
level	95 %

sides	2-sided
lower limit	2
upper limit	59.9

Notes:

[100] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0085 [101]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	41.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.2
upper limit	69.1

Notes:

[101] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1948 [102]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	19.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.8
upper limit	48.5

Notes:

[102] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0296 [103]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	30.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	58.5

Notes:

[103] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Hospital Anxiety and Depression Scale (HADS): Depression Subscale at Week 2, 4, 8 and 12

End point title	Change From Baseline in Hospital Anxiety and Depression Scale (HADS): Depression Subscale at Week 2, 4, 8 and 12

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D), both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	152	152	76	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-0.7 (-1.0 to -0.3)	-1.3 (-1.6 to -0.9)	-0.2 (-0.7 to 0.3)	
Change at Week 4	-1.1 (-1.6 to -0.7)	-1.7 (-2.1 to -1.3)	0.1 (-0.5 to 0.7)	
Change at Week 8	-1.0 (-1.4 to -0.6)	-2.0 (-2.4 to -1.6)	-0.3 (-0.9 to 0.3)	
Change at Week 12	-1.4 (-1.8 to -0.9)	-1.8 (-2.2 to -1.4)	-0.2 (-0.8 to 0.4)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1718
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0018
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	-0.4

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified

Analysis type	superiority
P-value	= 0.0005
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	-1.1

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0476
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	0

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	-1

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0028
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	-0.4

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	-0.9

Secondary: Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety Subscale at Week 2, 4, 8 and 12

End point title	Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety Subscale at Week 2, 4, 8 and 12

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D), both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	152	152	76	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-1.1 (-1.5 to -0.7)	-1.7 (-2.0 to -1.3)	-0.9 (-1.5 to -0.4)	
Change at Week 4	-1.4 (-1.9 to -1.0)	-2.2 (-2.6 to -1.8)	-1.0 (-1.6 to -0.4)	
Change at Week 8	-1.5 (-1.9 to -1.0)	-2.3 (-2.7 to -1.8)	-1.0 (-1.7 to -0.4)	
Change at Week 12	-1.6 (-2.0 to -1.1)	-2.1 (-2.5 to -1.6)	-1.0 (-1.7 to -0.4)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6134
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	0.5

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0422
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	0

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.205

Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	0.3

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0012
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	-0.5

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2657
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	0.3

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0019
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	-0.5

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1675
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	0.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0085
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	-0.3

Secondary: Percentage of Subjects With >=8 Points at Baseline and Achieving Score of <8 Points in Hospital Anxiety and Depression Scale: Anxiety Subscale at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With >=8 Points at Baseline and Achieving Score of <8 Points in Hospital Anxiety and Depression Scale: Anxiety Subscale at Week 2, 4, 8 and 12

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D), both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, “Number of Subjects Analyzed” signifies subjects evaluable for this end point and "Number Analyzed” signifies number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	34	18	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=33, 34, 18)	48.5	64.7	38.9	
Week 4 (n=32, 33, 18)	50.0	54.5	55.6	
Week 8 (n=33, 34, 18)	42.4	58.8	22.2	
Week 12 (n=33, 33, 18)	39.4	48.5	38.9	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5539 [104]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	8.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.6
upper limit	37.2

Notes:

[104] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0561 [105]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	27.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	55.1

Notes:

[105] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.746 [106]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage

Point estimate	-4.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.4
upper limit	23.7

Notes:

[106] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1 [107]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.3
upper limit	28.3

Notes:

[107] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1474 [108]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	46.2

Notes:

[108] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0123 [109]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	37.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.1
upper limit	62.5

Notes:

[109] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.976 [110]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.5
upper limit	27.6

Notes:

[110] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5965 [111]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	7.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.4
upper limit	36.1

Notes:

[111] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With >=8 Points at Baseline and Achieving Score of <8 Points in Hospital Anxiety and Depression Scale: Depression Subscale at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With >=8 Points at Baseline and Achieving Score of <8 Points in Hospital Anxiety and Depression Scale: Depression Subscale at Week 2, 4, 8 and 12

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D), both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point and "Number Analyzed" signifies number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	22	20	9	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=22, 20, 9)	45.5	60.0	22.2	
Week 4 (n=22, 19, 9)	68.2	68.4	55.6	
Week 8 (n=21, 20, 9)	57.1	70.0	66.7	
Week 12 (n=22, 20, 9)	50.0	75.0	33.3	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	31
Analysis specification	Pre-specified

Analysis type	superiority
P-value	= 0.2278 [112]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	58

Notes:

[112] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0996 [113]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	35.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	72.4

Notes:

[113] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	31
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4449 [114]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	14.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.6
upper limit	50.6

Notes:

[114] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4139 [115]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	16.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.6
upper limit	55.5

Notes:

[115] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	31
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.729 [116]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-6.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.7
upper limit	27.4

Notes:

[116] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.6585 [117]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	8.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.3
upper limit	44.6

Notes:

[117] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	31
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3638 [118]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	18.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.7
upper limit	55.1

Notes:

[118] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.055 [119]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	40.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	78.5

Notes:

[119] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With >=11 Points at Baseline and Achieving Score of <11 Points in Hospital Anxiety and Depression Scale: Anxiety Subscale at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With >=11 Points at Baseline and Achieving Score of <11 Points in Hospital Anxiety and Depression Scale: Anxiety Subscale at Week 2, 4, 8 and 12

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D), both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, “Number of Subjects Analyzed” signifies subjects evaluable for this end point and "Number Analyzed” signifies number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	13	8	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=16, 13, 8)	56.3	46.2	75.0	
Week 4 (n=16, 12, 8)	56.3	58.3	75.0	
Week 8 (n=16, 13, 8)	56.3	53.8	75.0	
Week 12 (n=16, 13, 8)	43.8	46.2	37.5	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	24
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4036 [120]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-18.8
Confidence interval	

level	95 %
sides	2-sided
lower limit	-58.4
upper limit	20.9

Notes:

[120] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.158 [121]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-35.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-75.9
upper limit	5.3

Notes:

[121] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	24
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.514 [122]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-14.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.5
upper limit	25.1

Notes:

[122] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4149 [123]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-19.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-63.3
upper limit	23.7

Notes:

[123] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	24
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4036 [124]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-18.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-58.4
upper limit	20.9

Notes:

[124] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2092 [125]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-30.7
Confidence interval	
level	95 %
sides	2-sided

lower limit	-70.9
upper limit	9.6

Notes:

[125] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	24
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5982 [126]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	11.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.1
upper limit	53

Notes:

[126] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8647 [127]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.3
upper limit	44.7

Notes:

[127] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects With >=11 Points at Baseline and Achieving Score of <11 Points in Hospital Anxiety and Depression Scale: Depression Subscale at Week 2, 4, 8 and 12

End point title	Percentage of Subjects With >=11 Points at Baseline and Achieving Score of <11 Points in Hospital Anxiety and Depression Scale: Depression Subscale at Week 2, 4, 8 and 12

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D), both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	8	3	
Units: percentage of subjects				
number (not applicable)				
Week 2	20.0	75.0	100.0	
Week 4	60.0	75.0	66.7	
Week 8	40.0	75.0	66.7	
Week 12	40.0	75.0	66.7	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0546 [128]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-78.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-117.5
upper limit	-39.6

Notes:

[128] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	11
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3573 [129]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-27.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-62.5
upper limit	6.7

Notes:

[129] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9219 [130]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-55.6
upper limit	48.5

Notes:

[130] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	11
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3173 [131]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	24.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.4
upper limit	63.6

Notes:

[131] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5408 [132]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-77
upper limit	27

Notes:

[132] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	11
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3173 [133]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	24.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.4
upper limit	63.6

Notes:

[133] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v PF-04965842 200 mg
Number of subjects included in analysis	13
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5408 [134]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	-25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-77
upper limit	27

Notes:

[134] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	11
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3173 [135]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	24.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.4
upper limit	63.6

Notes:

[135] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Patient-Oriented Eczema Measure (POEM) at Week 2, 4, 8 and 12

End point title	Change From Baseline in Patient-Oriented Eczema Measure (POEM) at Week 2, 4, 8 and 12

End point description:

POEM is a 7-item subject reported outcome measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28, where higher score indicated greater severity. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, “Number of Subjects Analyzed” signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	153	153	77	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-4.6 (-5.5 to -3.7)	-8.1 (-9.0 to -7.2)	-1.8 (-3.1 to -0.5)	
Change at Week 4	-6.2 (-7.2 to -5.1)	-10.8 (-11.8 to -9.8)	-2.4 (-3.9 to -0.9)	
Change at Week 8	-6.1 (-7.3 to -4.9)	-10.6 (-11.8 to -9.5)	-3.4 (-5.1 to -1.7)	
Change at Week 12	-6.8 (-8.0 to -5.6)	-10.6 (-11.8 to -9.4)	-3.7 (-5.5 to -1.9)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	-1.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority

P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-6.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	-4.7

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.6
upper limit	-2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-8.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.2
upper limit	-6.6

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0096
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	-0.7

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-7.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	-5.2

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo

Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0049
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	-0.9

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9
upper limit	-4.7

Secondary: Change From Baseline in Patient Global Assessment (PtGA) at Week 2, 4, 8 and 12

End point title	Change From Baseline in Patient Global Assessment (PtGA) at Week 2, 4, 8 and 12

End point description:

Subject responded to "Overall, how would you describe your Atopic Dermatitis right now?" on a scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	153	77	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	-0.6 (-0.8 to -0.5)	-1.1 (-1.2 to -0.9)	-0.3 (-0.5 to -0.1)	
Change at Week 4	-0.8 (-1.0 to -0.7)	-1.3 (-1.5 to -1.2)	-0.4 (-0.6 to -0.1)	
Change at Week 8	-1.0 (-1.1 to -0.8)	-1.4 (-1.6 to -1.2)	-0.5 (-0.7 to -0.2)	
Change at Week 12	-1.0 (-1.2 to -0.9)	-1.5 (-1.7 to -1.3)	-0.5 (-0.8 to -0.3)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	-0.1

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	-0.2

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.7

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	-0.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.6

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0014
Method	Mixed models analysis

Parameter estimate	Difference in LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	-0.2

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	-0.6

Secondary: Percentage of Subjects Achieving 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline in Patient Global Assessment (PtGA) at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline in Patient Global Assessment (PtGA) at Week 2, 4, 8 and 12

End point description:

Subject responded to “Overall, how would you describe your Atopic Dermatitis right now?” on a scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed” signifies subjects evaluable for this end point and “Number Analyzed” signifies the number of subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	153	151	75	
Units: percentage of subjects				
number (not applicable)				
Week 2 (n=153, 151, 75)	7.2	19.2	1.3	
Week 4 (n=151, 149, 74)	14.6	31.5	5.4	
Week 8 (n=151, 151, 71)	17.2	34.4	8.5	
Week 12 (n=152, 150, 73)	21.1	36.0	6.8	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0575 [136]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	11.7

Notes:

[136] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 [137]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	18.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.7
upper limit	25.5

Notes:

[137] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0411 [138]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	17.1

Notes:

[138] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [139]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	26.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.9
upper limit	35.5

Notes:

[139] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.0781 [140]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	8.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	18

Notes:

[140] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [141]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	26.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.2
upper limit	36.3

Notes:

[141] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0075 [142]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	14.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.3
upper limit	23.2

Notes:

[142] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [143]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	29.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.6
upper limit	38.9

Notes:

[143] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L): Index Value at Week 2, 4, 8 and 12

End point title	Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L): Index Value at Week 2, 4, 8 and 12

End point description:

EQ-5D-5L: standardized participant (aged >17 years) completed questionnaire consisted of 2 components: a health state profile and an optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQol. US value sets (with all possible health states) was used for adults in the study, range from 1 to -0.109. Higher (positive) scores = better health state. FAS analysis set. "N"=subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	121	119	60	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	0.049 (0.030 to 0.068)	0.084 (0.065 to 0.103)	0.016 (-0.011 to 0.043)	

Change at Week 4	0.062 (0.041 to 0.084)	0.092 (0.070 to 0.114)	0.037 (0.007 to 0.067)	
Change at Week 8	0.053 (0.029 to 0.077)	0.097 (0.074 to 0.121)	0.005 (-0.029 to 0.039)	
Change at Week 12	0.058 (0.034 to 0.083)	0.078 (0.054 to 0.103)	0.014 (-0.021 to 0.050)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0453
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.034
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.001
upper limit	0.066

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.068
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.036
upper limit	0.101

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1821
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.025
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.012
upper limit	0.062

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0038
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.055
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.018
upper limit	0.092

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0241

Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.048
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.006
upper limit	0.09

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.093
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.051
upper limit	0.134

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0461
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.044
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.001
upper limit	0.087

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0037
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.064
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.021
upper limit	0.107

Secondary: Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L)- Visual Analogue Scale Score at Week 2, 4, 8 and 12

End point title	Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L)- Visual Analogue Scale Score at Week 2, 4, 8 and 12

End point description:

EQ-5D-5L is a standardized subject completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional VAS. EQ-5D VAS was used to record a subject's (aged above 17 years) rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	121	119	60	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	5.586 (3.203 to 7.969)	9.697 (7.294 to 12.100)	1.038 (-2.361 to 4.437)	
Change at Week 4	6.207 (3.473 to 8.940)	11.931 (9.174 to 14.688)	1.846 (-2.005 to 5.696)	

Change at Week 8	6.982 (3.847 to 10.117)	10.740 (7.642 to 13.838)	0.937 (-3.528 to 5.402)	
Change at Week 12	8.604 (5.509 to 11.699)	10.409 (7.328 to 13.489)	1.035 (-3.451 to 5.520)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0319
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	4.548
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.397
upper limit	8.7

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	8.659
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.496
upper limit	12.822

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0702
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	4.361
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.362
upper limit	9.084

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	10.085
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.349
upper limit	14.821

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.03
Method	Mixed models analysis

Parameter estimate	Difference in LS mean
Point estimate	6.045
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.589
upper limit	11.501

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	9.803
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.368
upper limit	15.237

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	181
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0067
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	7.569
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.119
upper limit	13.019

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	9.374
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.933
upper limit	14.815

Secondary: Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y): Index Value at Week 2, 4, 8 and 12

End point title	Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y): Index Value at Week 2, 4, 8 and 12

End point description:

EQ-5D-Y: standardized subject (aged 12-17 years) completed questionnaire consisted of 2 components: a health state profile and an optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQol. UK value sets (with all possible health states) was used for adolescents in the study, range from 1 to -0.594. Higher (positive) scores = better health state. FAS analysis set. "N"=subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	31	32	16	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	0.115 (0.039 to 0.191)	0.209 (0.134 to 0.284)	0.119 (0.009 to 0.228)	
Change at Week 4	0.168 (0.071 to 0.265)	0.278 (0.183 to 0.374)	-0.006 (-0.149 to 0.137)	
Change at Week 8	0.122 (0.017 to 0.228)	0.198 (0.093 to 0.304)	0.118 (-0.040 to 0.275)	

Change at Week 12	0.160 (0.056 to 0.265)	0.215 (0.109 to 0.322)	0.153 (-0.007 to 0.314)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9568
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.004
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.137
upper limit	0.13

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1782
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.042
upper limit	0.223

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0491
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.174
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.001
upper limit	0.347

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0015
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.284
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.112
upper limit	0.456

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9638
Method	Mixed models analysis

Parameter estimate	Difference in LS mean
Point estimate	0.004
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.185
upper limit	0.194

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4016
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.109
upper limit	0.27

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9429
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.007
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.184
upper limit	0.198

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5212
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	0.062
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.13
upper limit	0.254

Secondary: Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y): Visual Analogue Scale Score at Week 2, 4, 8 and 12

End point title	Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y): Visual Analogue Scale Score at Week 2, 4, 8 and 12

End point description:

EQ-5D-Y is a standardized subject completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score specifically developed and validated for use by youths age 12-17 years. EQ-5D-Y consists of two components: a health state profile and an optional VAS. EQ-5D VAS was used to record a subject's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	32	16	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2	5.515 (0.318 to 10.712)	14.933 (9.742 to 20.124)	3.384 (-4.217 to 10.985)	
Change at Week 4	5.359 (-0.339 to 11.057)	15.496 (9.803 to 21.188)	-1.494 (-10.060 to 7.072)	
Change at Week 8	11.828 (5.736 to 17.919)	12.510 (6.345 to 18.674)	3.156 (-6.213 to 12.524)	

Change at Week 12	10.347 (5.347 to 15.347)	17.224 (12.151 to 22.297)	4.276 (-3.397 to 11.948)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6467
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	2.131
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.095
upper limit	11.358

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Statistical analysis description:	
Change at Week 2: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.	
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0147
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	11.549
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.338
upper limit	20.761

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1894
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	6.853
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.453
upper limit	17.159

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0015
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	16.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.699
upper limit	27.281

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1267
Method	Mixed models analysis

Parameter estimate	Difference in LS mean
Point estimate	8.672
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.518
upper limit	19.862

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1009
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	9.354
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.866
upper limit	20.573

Statistical analysis title	Placebo Vs PF-04965842 100 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1915
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	6.071
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.107
upper limit	15.249

Statistical analysis title	Placebo Vs PF-04965842 200 mg

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, week, treatment by week interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0064
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	12.948
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.754
upper limit	22.143

Secondary: Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) at Week 12

End point title	Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) at Week 12

End point description:

FACIT-F is a 13-item questionnaire. Subjects (aged above 17 years) scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Higher the subject's response to the questions (with the exception of 2 negatively stated) greater was the subject's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the subject's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (the best score) where higher scores indicated better overall health status (less fatigue). Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	106	108	49	
Units: units on a scale				
least squares mean (confidence interval 95%)	2.4 (0.8 to 3.9)	3.3 (1.7 to 4.8)	-1.3 (-3.6 to 1.0)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	155
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0102 [144]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	6.4

Notes:

[144] - Analysis of covariance (ANCOVA) model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	157
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013 [145]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	4.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	7.3

Notes:

[145] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Secondary: Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12

End point title	Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12

End point description:

Peds-FACIT-F is a 13-item questionnaire for adolescents of 12-17 years of age. Subjects scored each item on a 5-point scale: 0 (none of the time) to 4 (all of the time). Higher the subject's response to the questions (with the exception of 2 negatively stated), greater was the subject's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the subject's response). The sum of all responses resulted in the Peds-FACIT-F score for a total possible score of 0 (worse score) to 52 (the best score) where higher scores indicated better overall health status (less fatigue). Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	31	30	13	
Units: units on a scale				
least squares mean (confidence interval 95%)	2.2 (0.5 to 3.9)	2.1 (0.3 to 3.8)	1.2 (-1.4 to 3.9)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5241 [146]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	4.2

Notes:

[146] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5821 [147]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	4.1

Notes:

[147] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Secondary: Change From Baseline in Short Form-36 Version 2 (SF-36v2) Acute

Summary Score at Week 12: Physical Component Summary	
End point title	Change From Baseline in Short Form-36 Version 2 (SF-36v2) Acute Summary Score at Week 12: Physical Component Summary

End point description:

SF-36v2 health survey is a self-administered questionnaire consisting of 36 questions, measuring 8 health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. These domains were also summarized as physical and mental component summary scores. Physical component summary: the minimum score is 0 and the maximum score is 100. Higher scores indicates a better health state. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	106	108	50	
Units: units on a scale				
least squares mean (confidence interval 95%)	4.3 (3.0 to 5.6)	5.2 (3.9 to 6.5)	0.5 (-1.4 to 2.4)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	156
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013 [148]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.5
upper limit	6.1

Notes:

[148] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	158
Analysis specification	Pre-specified
Analysis type	superiority

P-value	< 0.0001 [149]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	4.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	7

Notes:

[149] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Secondary: Change From Baseline in Short Form-36v2 Acute Summary Score at Week 12: Mental Component Summary

End point title	Change From Baseline in Short Form-36v2 Acute Summary Score at Week 12: Mental Component Summary

End point description:

SF-36v2 health survey is a self-administered questionnaire consisting of 36 questions, measuring 8 health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. These domains were also summarized as physical and mental component summary scores. Mental component summary: the minimum score is 0 and the maximum score is 100. Higher scores indicates a better health state. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	106	108	50	
Units: units on a scale				
least squares mean (confidence interval 95%)	1.5 (-0.1 to 3.0)	2.8 (1.3 to 4.3)	-0.2 (-2.5 to 2.0)	

Statistical analyses

Statistical analysis title	Placebo Vs PF-04965842 100 mg
Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	156
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2256 [150]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	1.7
Confidence interval	
level	95 %

sides	2-sided
lower limit	-1
upper limit	4.4

Notes:

[150] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Statistical analysis title	Placebo Vs PF-04965842 200 mg
Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	158
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0275 [151]
Method	ANCOVA
Parameter estimate	Difference in LS mean
Point estimate	3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	5.8

Notes:

[151] - ANCOVA model was used including treatment as main effect and randomization strata (baseline disease severity and age category) and baseline value as covariates.

Secondary: Plasma Concentration Versus Time Summary of PF-04965842

End point title	Plasma Concentration Versus Time Summary of PF-

End point description:

Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ) = =1.00 nanogram per milliliter (ng/mL) to zero. Analysis set included all randomized subjects who received at least 1 dose of PF-04965842 and had pharmacokinetic measurements. Here, 'Number Analyzed' = subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Day 1 of Week 4: 0 hour(Pre-dose), 0.5 hours post-dose; Day 1 of Week 12: 0.5, 4 hours post-dose

Notes:

[152] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was performed for this endpoint

End point values	PF-04965842 100 mg	PF-04965842 200 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	142	144		
Units: ng/mL				
arithmetic mean (standard deviation)				
Week 4: 0 Hour (n=142, 144)	14.57 (± 65.044)	58.16 (± 162.11)		
Week 4: 0.5 Hour post dose (n=116, 121)	485.3 (± 393.36)	889.7 (± 786.96)		
Week 12: 0.5 Hour Post-dose (n=103, 106)	440.6 (± 373.81)	933.9 (± 741.09)		
Week 12: 4 Hour Post-dose (n=119, 122)	273.1 (± 176.37)	838.9 (± 544.29)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 16

Adverse event reporting additional description:

Same event may appear as adverse event (AE) and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 subject and as nonserious in another subject or 1 subject may have experienced both serious and nonserious event during study.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	21.1

Reporting groups

Reporting group title	PF-04965842 100 mg

Reporting group description:

Subjects were randomized to receive a tablet of PF-04965842 100 milligram (mg) and a tablet of matching placebo orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Reporting group title	PF-04965842 200 mg

Reporting group description:

Subjects were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Reporting group title	Placebo

Reporting group description:

Subjects were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Serious adverse events	PF-04965842 100 mg	PF-04965842 200 mg	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 156 (3.21%)	5 / 154 (3.25%)	3 / 77 (3.90%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 156 (0.00%)	2 / 154 (1.30%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 156 (0.64%)	0 / 154 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 156 (0.64%)	0 / 154 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal detachment			
subjects affected / exposed	1 / 156 (0.64%)	0 / 154 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Inflammatory bowel disease			
subjects affected / exposed	0 / 156 (0.00%)	1 / 154 (0.65%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 156 (0.64%)	0 / 154 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 156 (0.00%)	0 / 154 (0.00%)	1 / 77 (1.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Meniscal degeneration			
subjects affected / exposed	0 / 156 (0.00%)	0 / 154 (0.00%)	1 / 77 (1.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 156 (0.00%)	1 / 154 (0.65%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 156 (0.64%)	0 / 154 (0.00%)	1 / 77 (1.30%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillitis			
subjects affected / exposed	0 / 156 (0.00%)	1 / 154 (0.65%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PF-04965842 100 mg	PF-04965842 200 mg	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	65 / 156 (41.67%)	65 / 154 (42.21%)	26 / 77 (33.77%)
Nervous system disorders			
Headache			
subjects affected / exposed	12 / 156 (7.69%)	15 / 154 (9.74%)	2 / 77 (2.60%)
occurrences (all)	13	18	2
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	14 / 156 (8.97%)	31 / 154 (20.13%)	2 / 77 (2.60%)
occurrences (all)	15	33	2
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	22 / 156 (14.10%)	8 / 154 (5.19%)	13 / 77 (16.88%)
occurrences (all)	22	9	13
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	23 / 156 (14.74%)	18 / 154 (11.69%)	8 / 77 (10.39%)
occurrences (all)	24	18	11
Upper respiratory tract infection			
subjects affected / exposed	11 / 156 (7.05%)	11 / 154 (7.14%)	5 / 77 (6.49%)
occurrences (all)	12	11	6

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 November 2017	Electrocardiography (ECG) exclusion criteria, and discontinuation criteria were added for subject safety until further evaluation of QT data for Janus kinase 1 (JAK1) was obtained. Revisions to planned ECG assessments included addition of single ECG assessments at study visits 4, 5, 7 and follow-up, clarification that the baseline ECG was routinely performed for all subjects, revision of exclusion criterion was to exclude additional factors associated with QT/ QT interval with Fridericia's correction (QTcF) abnormalities and confirmation that Fridericia's correction was used, and addition of a discontinuation criterion for prolonged QTcF interval.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported